C-CAMP and GARDP collaborate to tackle global health threat of antimicrobial resistance

5 December 2022

Bangalore, 5 December 2022 – The Centre for Cellular and Molecular Platforms (C-CAMP) has joined forces with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the global problem of resistant bacterial infections. Both parties plan to assist in fast-tracking the clinical development, validation and integration of innovative diagnostic solutions for antimicrobial resistance (AMR) into the health system for access by end-users including clinicians, laboratories, and hospitals.

This letter of intent, which was signed by GARDP and C-CAMP, underlines C-CAMP’s growing prominence as a global destination for cutting-edge AMR innovations. Dr Saiyed welcomed the signing, saying, “This collaboration would allow C-CAMP to leverage its significant network in the Indian innovation ecosystem to identify, nurture, and scale up innovative solutions in India and beyond. Our collaboration with GARDP will help especially in clinical development and validation of C-CAMP-supported AMR solutions, with the larger goal of driving sustainable and ethical access to emerging technologies. This access will be crucial to bending the growing curve of AMR in India and abroad.”

“The letter of intent with C-CAMP recognizes the significant role India plays in providing global AMR solutions,” said Dr François Franceschi. “It is an important opportunity to explore synergies in evaluating and providing feedback for the clinical development of urgently needed innovative diagnostic solutions to help tackle AMR globally, with emphasis on solutions that are also deployable in low- and middle-income countries.”


The letter of intent was signed at the C-CAMP office by Dr Taslimarif Saiyed (right), CEO and Director of C-CAMP, Dr François Franceschi (left), Head of Asset Evaluation and Development at GARDP, and Dr Subasree Srinivasan (standing), GARDP Medical Director.

About Centre for Cellular and Molecular Platforms

Centre for Cellular and Molecular Platforms (C-CAMP) is India’s premier innovation and technology hub and one of the largest and most vibrant life sciences incubators in the country. C-CAMP has directly funded, incubated and mentored 330+ start-ups over half a decade and is connected to over 2000 start-ups and entrepreneurs across the country in healthcare, agriculture and environment. C-CAMP has established several state-of-the-art technology platforms for facilitating cutting-edge research in the biosciences which have supported 220+ publications. C-CAMP is an initiative supported by Govt of India agencies including Department of Biotechnology, Department of Science & Technology, NITI Aayog-AIM, Ministry of Electronics and Information Technology, Startup India and Department of IT, BT, S&T Government of Karnataka. It has several international partnerships spread across US, UK, Netherlands, Denmark, Switzerland, Japan, Brazil and Israel.


The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created in 2016 by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. It aims to develop new treatments to fight drug-resistant infections, with a focus on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children. GARDP is funded by the governments of Australia, Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, the Canton of Geneva, as well as Médecins Sans Frontières and private foundations. GARDP is registered under the legal name GARDP Foundation. www.gardp.org